Syndesi Therapeutics Overview

  • Founded
  • 2018
  • Status
  • Acquired/​Merged
  • Employees
  • 13
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1B
Latest Deal Amount

Syndesi Therapeutics General Information


Developer of drug molecules designed to treat cognitive impairment. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right therapy at their disposal.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Parent Company
Primary Office
  • Chemin du Cyclotron 6
  • 1348 Ottignies-Louvain-la-Neuve
  • Belgium
+32 010 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Syndesi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Mar-2022 $1B 0000 000 Completed Generating Revenue
5. Early Stage VC 01-Jun-2021 00.000 0000 000.00 Completed Generating Revenue
4. Early Stage VC 16-Jun-2020 00.000 000.00 000.00 Completed Generating Revenue
3. Early Stage VC 20-Dec-2018 00.000 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 01-Feb-2018 $20.8M $20.8M 000.00 Completed Startup
1. Accelerator/Incubator 01-Jan-2018 Completed Startup
To view Syndesi Therapeutics’s complete valuation and funding history, request access »

Syndesi Therapeutics Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class A 0,000,000 00.0 00.0 00 00.0 00.000
To view Syndesi Therapeutics’s complete cap table history, request access »

Syndesi Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Jonathan Savidge Ph.D Chief Executive Officer
John Kemp Ph.D Chief Scientific Officer
Torsten Madsen Ph.D Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Syndesi Therapeutics Board Members (9)

Name Representing Role Since
Aidan King Fountain Healthcare Partners Board Member 000 0000
Christina Takke Ph.D V-Bio Ventures Board Member 000 0000
Emmanuel Lacroix Ph.D UCB (Biotechnology) Board Member 000 0000
Fiona MacLaughlin Ph.D Self Board Member 000 0000
Jean Combalbert Ph.D Self Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Syndesi Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syndesi Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fountain Healthcare Partners Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
Société Régionale d'Investissement de Wallonie Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »